<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31831">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971918</url>
  </required_header>
  <id_info>
    <org_study_id>2013/006/HP</org_study_id>
    <nct_id>NCT01971918</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics</brief_title>
  <acronym>STRADA</acronym>
  <official_title>Comparative Analysis of Two Therapeutic Strategies: &quot;Early Switch&quot; Versus &quot;Therapeutic Intensification&quot; in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate two therapeutic strategies: &quot;early switch&quot; or
      &quot;therapeutic intensification&quot; in patients with spondyloarthritis in case of secondary
      treatment failure suspicion to a first monoclonal antibodies anti-TNF definite by increase
      of ASDAS and positivity to ADAb.

      Patients and Methods:

      Multicentric randomized prospective study. Duration of inclusion 30 months. Duration of
      follow-up 24 months. 104 patients with spondyloarthritis treated with infliximab or
      adalimumab will be included if their ADAb dosage is positive, and they will be randomized
      (1:1) in two groups : &quot;early switch&quot; where treatment will be change to another anti-TNF, or
      &quot;therapeutic intensification&quot; where interval between two injections will be shortened.
      Patients will be evaluated clinically (ASDAS) and biologically (ADAb) at 12 weeks then at 24
      weeks. Principal outcome will be the  variation of ASDAS between baseline and end of the
      study. Number of patients to be included has been determined statistically from a
      preliminary study (power &gt;98% for ASDAS variation of 20% on week 24).

      Expected results:

      On week 24, we expect a better response and a greater proportion of patients in remission in
      the &quot;early switch&quot; arm compare to the &quot;therapeutic intensification&quot; arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Variation of ASDAS between inclusion and 24 weeks of treatment</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>ASDAS will be measured at week 24 and will be compared to day 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients with ASDAS &lt; 2.1</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of patients with ASDAS &lt; 2.1 at week 24 ASDAS &lt; 2.1 is considered as remission</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety analysis - Occurence of adverse event</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>safety analysis in each arm at week 24 Safety analysis include occurence of adverse event in each arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>early switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early switch of monoclonal antibodies anti-TNF
anti drug antibodies dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>therapeutic intensification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic intensification of monoclonal antibodies anti-TNF
anti drug antibodies dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti drug antibodies dosage</intervention_name>
    <description>anti drug antibodies dosage</description>
    <arm_group_label>early switch</arm_group_label>
    <arm_group_label>therapeutic intensification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spondyloarthritis positive for the ASAS criteria, treated with a first biologic :
             infliximab ( 5mg/kg intravenously every 8 weeks) or adalimumab (40mg subcutaneously
             every 2 weeks)

          -  Active spondyloarthritis definite by ASDAS-CRP &gt; 2.1 at two successive evaluations
             while patient was previously responder (ASDAS&lt;2.1 at least once in the 6th months
             after beginning of treatment)

          -  Positivity to anti-drug antibodies (ADAb)

          -  Consent of the patient

          -  No contra-indication to another anti-tnf biologic

          -  affiliation to health insurance

          -  woman of childbearing age must use an appropriate mean of contraception

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  contra-indication to anti-tnf biologic

          -  patient with known hypersensitivity to any of the excipients

          -  Severe and uncontrolled opportunistic infection , includins septicemia, tuberculosis,
             abcess and opportunistic infection

          -  Evolutive infection, including chronic or localised infection

          -  Patient with moderate to severe heart failure (NYHA class III/IV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier VITTECOQ, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Rouen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier VITTECOQ, Prof</last_name>
    <phone>+3323288</phone>
    <phone_ext>9019</phone_ext>
    <email>olivier.vittecoq@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu VERDET, Dr</last_name>
    <phone>+3323288</phone>
    <phone_ext>9019</phone_ext>
    <email>mathieu.verdet@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>60</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice FARDELLONE, Prof</last_name>
      <phone>+3332266</phone>
      <phone_ext>8250</phone_ext>
      <email>fardellone.patrice@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice FARDELLONE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian MARCELLI, Prof</last_name>
      <phone>+3323106</phone>
      <phone_ext>4749</phone_ext>
      <email>marcelli-c@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Christian MARCELLI, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dieppe Hospital</name>
      <address>
        <city>Dieppe</city>
        <zip>76202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia NICOLAU, Dr</last_name>
      <phone>+3323214</phone>
      <phone_ext>74 97</phone_ext>
      <email>JNicolau@ch-dieppe.fr</email>
    </contact>
    <investigator>
      <last_name>Julia NICOLAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elbeuf Hospital</name>
      <address>
        <city>Elbeuf</city>
        <zip>76410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando DA SILVA, Dr</last_name>
      <phone>+3323296</phone>
      <phone_ext>3576</phone_ext>
      <email>fernando.dasilva@chi-elbeuf-louviers.fr</email>
    </contact>
    <investigator>
      <last_name>Fernando DA SILVA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René M FLIPO, Prof</last_name>
      <phone>+3332044</phone>
      <phone_ext>6120</phone_ext>
      <email>rmflipo@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>René M FLIPO, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Havre Hospital</name>
      <address>
        <city>Montivilliers</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles zarnitsky, Dr</last_name>
      <phone>+3323273</phone>
      <phone_ext>3378</phone_ext>
      <email>charles.zarnitsky@ch-havre.fr</email>
    </contact>
    <investigator>
      <last_name>Charles zarnitsky, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier VITTECOQ, Prof</last_name>
      <phone>+3323288</phone>
      <phone_ext>9019</phone_ext>
      <email>olivier.vittecoq@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier VITTECOQ, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>October 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spondyloarthritis</keyword>
  <keyword>monoclonal antibodies anti-TNF</keyword>
  <keyword>secondary treatment failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Anti-Idiotypic</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
